Powering Next-Level Analytics: ProJect Pharmaceutics’s expanded lab welcomes the Orbitrap Exploris 240 LC-MS to elevate formulation science
ProJect Pharmaceutics is excited to open newly expanded lab space, now home to our most recent acquisition: the Orbitrap Exploris 240 LC-MS – a cutting edge, high-resolution platform capturing complex molecular insights and delivering deeper analytical clarity for complex formulation challenges. Curious what next-level analytics can do for your project? The multi-attribute method (MAM), a […]
Today, we proudly celebrate our 15th company anniversary! 🎉
Since 2010, ProJect Pharmaceutics CRO has stood for high-level formulation and process development for injectable parenterals. Today, we proudly look back on 15 successful years. We are truly grateful to our dedicated team, valued clients, and trusted partners who have been part of this journey. A sincere thank you to our partners and customers for […]
ProJect Pharmaceutics announces a new partnership with Afinum to support the next phase of its growth.
Munich, Germany, September 11, 2025 / — As a leading specialist in the formulation and process development of biologics and complex small molecules—particularly antibody-drug conjugates (ADCs) and virus-based therapeutics—the company ProJect Pharmaceutics views this collaboration as a significant step in accelerating its expansion. Founders Dr. Andreas SchĂĽtz and Mr. Klaus Hellerbrand will remain substantial co-investors […]
ProJect Pharmaceutics’ announces extension of service offering: In-use stability studies
ProJect Pharmaceutics has extended its capabilities to conduct in-use stability studies. The current portfolio on in-use stability services was topped by the addition of several perfusor pumps, as well as the operation of a red-light laboratory (to handle light-sensitive substances). We have the necessary laboratories, technical equipment, consumables and expertise to replicate the conditions for […]
ProJect Pharmaceutics receives CIR application renewal (Research Tax Credit) for the benefit of its French customers towards 2025
ProJect Pharmaceutics is a contract research and development organization (CRO) specialized in formulation and process development for parenteral drug products. Expanding the offering of its service portfolio towards the French customer base, ProJect Pharmaceutics was engaged to apply at the French Ministère de L’Enseignement SupĂ©rieur, De La Recherche Et De L’Innovation for eligibility to join […]
ProJect Pharmaceutics was granted a US patent on a novel liquid formulation of Bendamustine
ProJect Pharmaceutics was granted a US patent on a novel formulation which effectively stabilizes the anti-cancer drug Bendamustine and other N-mustard cancer drugs like Chlorambucil, Melphalan, Melflufen, etc. in liquid state at room temperature for up to 24 months. LIQUID PHARMACEUTICAL FORMULATION US-Patent No: 11,752,135 US-Application No: 17/042,795 Contact us for: – Details of the […]
ProJect Pharmaceutics’ announces new service offering: Excipient quantification
Are you looking for a CRO that quantifies the excipients in your formulation? Particularly for high concentrated protein formulations, a deep understanding of the Donnan effect in your specific formulation is of significant importance. We at ProJect Pharmaceutics have at your disposal the expertise, as well as state-of-the art chromatographic and spectroscopic analysis methods, for […]
Follow us on LinkedIn
ProJect Pharmaceutics is a contract research and development organization (CRO) specialized in formulation and process development for parenteral drug products. To support our client base and next generation customers alongside their formulation development needs, the company does posts on LinkedIn on a regular basis highlighting i.e. common problems we solve for our clients, tips and […]
ProJect Pharmaceutics’ announces new service offering: Determination of the molar protein extinction coefficient according to ICHQ6
Do you know the molar extinction coefficient of your (biologics) drug product? According to ICHQ6 the molar extinction coefficient needs to be experimentally determined for drug products. Here at ProJect Pharmaceutics, we are able to determine the extinction coefficient experimentally using an absolute gravimetric determination approach. Thereby we are able to consider not only the […]
FDA approval of a client’s small molecule drug product for i.v. injection
ProJect Pharmaceutics is proud to have contributed with its services, expertise and knowledge to develop a lyophilized i.v. injection formulation for one of its clients’ drug products which was approved by the U.S. Food and Drug Administration (FDA). Goal of the development was to move from an oral administration of the drug to an injectable […]